Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
CHARM Therapeutics logo — Protein-ligand intelligence to deliver next generation small...

CHARM Therapeutics

Protein-ligand intelligence to deliver next generation small molecule therapeutics

Founded 2021 United Kingdom London, United Kingdom 30 employees Series B Total: $162.60M AI, Biotechnology +1

General Information

Company Name CHARM Therapeutics
Founded Year 2021
Location United Kingdom London, United Kingdom
Employees 30
Industries AI, Biotechnology, Life Sciences
Funding Stage Series B
Business Model B2B
Revenue Model Licensing, Product Sales, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with CHARM Therapeutics. To contact CHARM Therapeutics, visit charmtx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does CHARM Therapeutics compare?

A PDF of CHARM Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting CHARM Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About CHARM Therapeutics

CHARM Therapeutics, founded in 2021 and headquartered in the United Kingdom, is transforming the landscape of small molecule therapeutics with its pioneering approach in the AI, Biotechnology, and Life Sciences industries.

Under the slogan "Protein-ligand intelligence to deliver next generation small molecule therapeutics," the company focuses on addressing challenges in acute myeloid leukemia (AML) treatment. Its lead program features a next-generation menin inhibitor designed to counteract resistance mutations, a significant limitation of first-generation solutions. This cutting-edge strategy positions CHARM as a frontrunner in delivering the durable responses that patients critically require.

In a demonstration of confidence in its potential, the company secured a substantial $80.00M Series B investment on 01 September 2025. This round was backed by prominent investors including F-Prime Capital, Khosla Ventures, Nvidia, OrbiMed, NEA, and SR One.

Business keywords: Protein-ligand intelligence, Next-generation small molecule therapeutics, Menin inhibitor, Acute myeloid leukemia, Resistance mutations, Durable responses, 3D deep learning, Drug discovery technologies, Undruggable disease targets, Transformational medicines, Clinical resistance mutations, Cutting-edge therapeutics

Services & Products

Development of next-generation menin inhibitors
Transformational medicines for acute myeloid leukemia
AI-driven drug discovery

Target Customers

Oncologists Cancer patients, particularly those with AML Pharmaceutical researchers

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $80.00M 6
F-Prime Capital Khosla Ventures Nvidia
F-Prime Capital, Khosla Ventures +4
01 Sep 2025
Early VC $20.00M 1
nVentures
nVentures
01 Apr 2023
Series A $50.00M 6
F-Prime Capital Khosla Ventures General Catalyst
F-Prime Capital, Khosla Ventures +4
01 Jun 2022
Early VC $12.60M -
01 Oct 2021

Latest News

View All
These are the European startups Nvidia backed in 2025, as it ramped up investing in the continent's... — Cnbc
These are the European startups Nvidia backed in 2025, as it ramped up investing in the continent's AI companies
Cnbc Jan 26, 2026
Amgen acquires Oxford-based Dark Blue in deal worth up to €718 million to advance leukemia programme — Eu-startups
Amgen acquires Oxford-based Dark Blue in deal worth up to €718 million to advance leukemia programme
Eu-startups Jan 07, 2026
€99 million Series D fuels Artios’ expansion of precision cancer treatment pipeline — Eu-startups
€99 million Series D fuels Artios’ expansion of precision cancer treatment pipeline
Eu-startups Nov 17, 2025
Edinburgh-based BioTech Trogenix lands €80 million to accelerate curative cancer treatments — Eu-startups
Edinburgh-based BioTech Trogenix lands €80 million to accelerate curative cancer treatments
Eu-startups Oct 06, 2025
London’s CHARM Therapeutics raises €68.5 million financing to tackle treatment-resistant cancers — Eu-startups
London’s CHARM Therapeutics raises €68.5 million financing to tackle treatment-resistant cancers
Eu-startups Sep 02, 2025

CHARM Therapeutics Alternatives & Competitors

View All Alternatives
CHARM Therapeutics vs
Ajax Therapeutics
Ajax Therapeutics

Biopharmaceutical company developing next generation JAK inhibitors for patients with myeloprolifera...

Acquired
12 employees
Biotechnology, Life Sciences
CHARM Therapeutics vs
Meddenovo Drug Design
Meddenovo Drug Design France

Meddenovo offers a unique blend of AI technologies and molecular modeling to design cyclic peptide t...

Seed
10 employees
AI, Biopharma
CHARM Therapeutics vs
Pentixapharm AG
Pentixapharm AG Germany

improves the life of patients with malignant diseases through targeted molecular diagnostic and ther...

Series A
33 employees
Biotechnology, Health Care
View all alternatives

FAQ About CHARM Therapeutics

Protein-ligand intelligence to deliver next generation small molecule therapeutics
CHARM Therapeutics was founded in 2021.
CHARM Therapeutics is headquartered in London, United Kingdom.
CHARM Therapeutics operates in AI, Biotechnology and Life Sciences. Its work centres on Protein-ligand intelligence, Next-generation small molecule therapeutics, Menin inhibitor and Acute myeloid leukemia. Its customers include Oncologists, Cancer patients, particularly those with AML and Pharmaceutical researchers.
CHARM Therapeutics has a B2B business model. Its revenue comes from Licensing, Product Sales and Service Fee.
CHARM Therapeutics has approximately 30 employees.
CHARM Therapeutics has completed 4 funding rounds, raising a total of $162.60M. The latest funding stage is Series B.
CHARM Therapeutics offers: Development of next-generation menin inhibitors, Transformational medicines for acute myeloid leukemia, AI-driven drug discovery.
Top alternatives and competitors to CHARM Therapeutics include Ajax Therapeutics, Meddenovo Drug Design, Pentixapharm AG, Synnovation Therapeutics, Sudo Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CHARM Therapeutics and Ajax Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for CHARM Therapeutics, https://bouncewatch.com/company/charm-therapeutics, updated 20 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes